Multiple sclerosis: Side effects of interferon beta therapy and their management

Neurology

Volumn 53, Issue 8, 1999, Pages 1622-1627

  Walther, E U ^a   Hohlfeld, R ^a,b  

^a Institute of Clinical Neuroimmunology   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Interferon beta; MS; Side effects; Therapy

Indexed keywords

ANTIDEPRESSANT AGENT; BACLOFEN; BETA INTERFERON; BETA1A INTERFERON; HYDROCORTISONE; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PREDNISONE;

ALOPECIA; ANAPHYLACTIC SHOCK; AUTOIMMUNE DISEASE; CAPILLARY LEAK SYNDROME; DEPRESSION; DISEASE ACTIVITY; FLU LIKE SYNDROME; HEADACHE; HUMAN; INJECTION SITE; INSOMNIA; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SPASTICITY; THROMBOCYTOPENIC PURPURA;

EID: 0033544299     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.8.1622     Document Type: Review

References (69)

1. The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. The IFNβ Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
3. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
4. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
5. PRISMS (Prevention of Relapses, Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferonβ-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
6. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
7. Paty DW, on behalf of the SPIMS (Secondary Progressive Interferon beta-1a MS) Study Group. Results of the 3-year, double-blind, placebo-controlled study of interferon beta-1a (Rebif) in secondary-progressive MS. J Neurol 1999;246(suppl 1):I/15. Abstract.
8. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46:12-18.
9. Munschauer FE 3rd, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997;19:883-893.
10. Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995;45:2173-2177.
11. 1b treatment decreases tumor necrosis factor-α and increases interleukin-6 production in multiple sclerosis. Neurology 1996;46:1633-1638.
12. Arnason BGW, Reder AT. Interferons and multiple sclerosis. Clin Neuropharmacol 1994;17:495-547.
13. Rice GPA, Ebers GC, Lublin FD, Knobler RL. Ibuprofen treatment versus gradual introduction of interferonβ-1b in patients with MS. Neurology 1999;52:1893-1895.
14. Río J, Nos C, Marzo ME, Tintoré M, Montalban X. Low-dose steroids reduce flu-like symptoms at the initiation of IFNβ-1b in relapsing-remitting MS. Neurology 1998;50:1910-1912.
15. Martínez-Cáceres EM, Río J, Barrau M, et al. Amelioration of flulike symptoms at the onset of interferon β-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. Ann Neurol 1998;44:682-685.
16. Weber F, Polak T, Günther A, et al. Synergistic immunomodulatory effects of interferon-β1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998;44:27-34.
17. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-237.
18. Bramati P, Sessa E, Rifici C, et al. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology 1998;51:1720-1723.
19. Khan OA, Hebel JR. Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon β-1b in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998;44:138-139.
20. Betaseron (interferon beta-1b), prescribing information. Richmond, CA: Berlex Laboratories, July 1993.
21. Avonex (interferon beta-1a), prescribing information. Cambridge, MA: Biogen Inc., May 1996.
22. Rebif (interferon beta-1a), prescribing information. Oakville, Ontario: Serono Canada, 1998.
23. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994;10:115-150.
24. Kauppila A, Cantell K, Janne O, Kokko E, Vihko R. Serum sex steroid and peptide hormone concentrations, and endometrial estrogen and progestin receptor levels during administration of human leukocyte interferon. Int J Cancer 1982;29: 291-294.
25. Pakulski LA, DiMarco LM. Severe vaginal bleeding associated with recombinant interferon beta-1b. Ann Pharmacother 1997;31:50-52.
26. Trown PW, Wills RJ, Kamm JJ. The preclinical development of Roferon-A. Cancer 1986;57(suppl 8):1648-1656.
27. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorders and multiple sclerosis. Arch Neurol 1987;44:376-378.
28. Rao SM. Neuropsychology of multiple sclerosis. J Clin Exp Neuropsychol 1986;8:503-542.
29. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991;41:1193-1196.
30. Stenager EN, Stenager E, Koch-Henriksen N, et al. Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry 1992;55:542-545.
31. Mohr DC, Goodkin DE, Likosky W, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996;2:222-226.
32. Borras C, Rio J, Porcel J, Barrios M, Tintore M, Montalban X. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b. Neurology 1999;52:1636-1639.
33. Fukunishi K, Tanaka H, Maruyama J, et al. Burns in a suicide attempt related to psychiatric side effects of interferon. Burns 1998;24:581-583.
34. Neilly LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996;46:552-554.
35. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-533.
36. Mohr DC, Goodkin DE, Gatto N, Van Der Wende J. Depression, coping and level of neurological impairment in multiple sclerosis. Mult Scler 1997;3:254-258.
37. Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum. J Am Acad Dermatol 1997;37:553-558.
38. Mehta CL, Tyler RJ, Cripps DJ. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon β-1b injections. J Am Acad Dermatol 1998;39:1024-1028.
39. Gaines AR, Varricchio F. Interferon beta-1b injection site reactions and necroses. Mult Scler 1998;4:70-73.
40. van Rengen A, Goossens A. Local reactions after subcutaneous injections of β-interferon. Contact Dermatitis 1997;39:209.
41. Rieger-Ziegler V, Kränke B, Soyer P, Aberer W. [Large cutaneous-subcutaneous infiltrates: a side effect of interferon beta injections]. Hautarzt 1998;49:310-312.
42. Knobler RL, Kelley CL, Trantas F, Webster GF, Lublin FD. Interferon beta-1b induced ulcerative skin lesions in MS. J Neuroimmunol 1994;54:173. Abstract.
43. Weinberg JM, Wolfe JT, Sood S, Saruk M, Rook AH, Spiers EM. Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature. Acta Derm Venerol (Stockh) 1997;77:146-148.
44. Vial T, Descotes J. Immune mediated side effects of cytokines in humans. Toxicology 1995;105:31-57.
45. Blake G, Murphy S. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment. Neurology 1997;49:1747-1748.
46. Harada H, Tamaoka A, Kohno Y, Mochizuki A, Shoji S. Exacerbation of myasthenia gravis in a patient after interferon-β treatment for chronic active hepatitis C. J Neurol Sci 1999; 165:182-183.
47. Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol 1997;54:1169-1190.
48. Durelli L, Bongioanni MR, Ferrero B, Oggero A, Marzano A, Rizzetto M. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 1998;50:570-571.
49. Linden D. Severe Raynaud's phenomenon associated with interferon-β treatment for multiple sclerosis. Lancet 1998; 352:878-879.
50. Alsalameh S, Manger B, Kern P, Kalden J. New onset of rheumatoid arthritis during interferon β-1b treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. Arthritis Rheum 1998;41:754. Letter.
51. Levesque MC, Ward FE, Jefferey DR, Weinberg JB. Interferon β-1a-induced polyarthritis in a patient with the HLA-DRB1*0404 allele. Arthritis Rheum 1999;42:569-573.
52. Nousari HC, Kimyai-Asadi A, Tausk FA. Subacute cutaneous lupus erythematodes associated with interferon beta-1a. Lancet 1998;352:1825-1826.
53. 1a in relapsing-remitting multiple sclerosis. Acta Neurol Scand 1997;96:372-374.
54. Kivisakk P, Lundahl J, von Heigl Z, Fredrikson S. No evidence for increased frequency of autoantibodies during interferon-beta 1b treatment of multiple sclerosis. Acta Neurol Scand 1998;97:320-323.
55. Durelli L, Ferrero B, Oggero A, et al. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 1999;162:74-83.
56. Schmidt S, Hertfelder HJ, von Spiegel T, et al. Lethal capillary-leak syndrome following a single administration of interferon beta-1b. Neurology 1999;53:220-222.
57. Lappin DF, Birnie GD, Whaley K. Modulation by interferons of the expression of monocyte complement genes. Biochem J 1990;268:387-392.
58. Ubara Y, Hara S, Takedatu H, et al. Hemolytic uremic syndrome associated with β-interferon therapy for chronic hepatitis C. Nephron 1998;80:107-108.
59. Sugano S, Suzuki T, Watanabe M, Ohe K, Ishii K, Okajima T. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1998;93:2441-2444.
60. Herrera WG, Balizet LB, Harberts SW, Brown ST. Occurrence of a TTP-like syndrome in two women receiving beta interferon therapy for relapsing multiple sclerosis. Neurology 1999; 52(suppl 2):A135. Abstract.
61. Corona T, Leon C, Ostrosky-Zeichner L. Severe anaphylaxis with recombinant interferon beta. Neurology 1999;52:425.
62. Clear D. Anaphylactoid reaction to methyl prednisolone developing after starting treatment with interferon β-1b. J Neurol Neurosurg Psychiatry 1999;66:690. Letter.
63. Quesada JR, Gutterman JU. Psoriasis and interferon alpha. Lancet 1986;1:1466-1468.
64. Webster GF, Knobler RL, Lublin FD, Kramer EM, Hochman LR. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996;34:365-367.
65. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998;139:380-395.
66. Kanda Y, Shigeno K, Matsuo H, Yano M, Yamada N, Kumagami H. Interferon-induced sudden hearing loss. Audiology 1995;34:98-102.
67. Tosti A, Misciali C, Bardazzi F, Fanti PA, Varotti C. Telogen effluvium due to recombinant interferon alpha-2b. Dermatology 1992;184:124-125.
68. Cirelli R, Herne KB, McCrary ML, Tyring SK. Adverse effects of interferons. In: Reder AT, ed. Interferon therapy of multiple sclerosis. New York: Marcel Dekker Inc., 1997:445-478.
69. The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b. Experience during the first three years. Neurology 1996;47:889-894.